IMARC Group’s latest report, titled “Malaria Vaccine Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2030,” finds that the global malaria vaccine market is anticipated to exhibit a CAGR of around 34% during 2022-2030. Malaria vaccines are biological components that promote the formation of antibodies to reduce the risk of developing malaria, a disease caused by the plasmodium parasite, which is spread to humans through the bites of infected mosquitoes. It is generally characterized by headaches, chills, fever, fatigue, nausea, and other symptoms. Some commonly used malaria vaccines include pre-erythrocytic, erythrocytic, and multi-antigen vaccines. They can be administered through intramuscular, subcutaneous, and intradermal injections. In recent years, malaria vaccines have gained immense traction across the globe to prevent the risk of contracting malaria.
Global Malaria Vaccine Market Trends:
The rising prevalence of malaria, especially across tropical countries, represents the primary factor driving the market growth. Moreover, the development of anti-infective or pre-erythrocytic vaccines that kill the plasmodium parasite and prevent the progression of chronic blood-stage disorders is positively influencing market growth. Additionally, numerous favorable initiatives by various government and non-government organizations to spread awareness about the importance of immunization and disease prevention among the masses are other major growth-inducing factors. Along with this, the increasing number of routine immunization programs in various countries, particularly in the endemic and rural regions, is propelling the market growth. Besides this, the rising focus of pharmaceutical companies on the development of new and improved malaria vaccines by accelerating the clinical trials of various pipeline drugs has catalyzed market growth. Furthermore, numerous technological advancements, including the introduction of novel adjuvants and innovative vaccination delivery platforms, are contributing to the market growth. Other factors, including ongoing research and development (R&D) activities, the launch of innovative product variants, extensive investments in improving healthcare infrastructure, and increasing funding for vaccine development programs, are also anticipated to create a favorable market outlook.
Market Summary:
- Based on the type, the market has been divided into pre-erythrocytic, erythrocytic, multi-antigen, and other vaccines.
- On the basis of the agent, the market has been segmented into Plasmodium Falciparum, Plasmodium Vivax, and Anopheles Species.
- The market has been segregated based on the route of administration into intramuscular, subcutaneous, intradermal, and others.
- Based on the distribution channel, the market has been categorized into NGO/non-profit organization, hospital pharmacy, retail pharmacy, online pharmacy, and others.
- Region-wise, the market has been divided into North America, Asia-Pacific, Europe, Latin America, and Middle East and Africa.
- The competitive landscape of the market has also been examined, along with the detailed profiles of key players operating in the industry.
About Us:
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Contact Us:
IMARC Group
30 N Gould St, Ste
Sheridan, WY (Wyoming) 82801 USA
Email: Sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800